Lipid re-screening: what is the best measure and interval?
- PMID: 19528038
- DOI: 10.1136/hrt.2009.172619
Lipid re-screening: what is the best measure and interval?
Abstract
Objectives: To estimate the long-term true change variation ('signal') and short-term within-person variation ('noise') of the different lipid measures and evaluate the best measure and the optimal interval for lipid re-screening.
Design: Retrospective cohort study from 2005 to 2008.
Setting: A medical health check-up programme at a centre for preventive medicine in a teaching hospital in Tokyo, Japan.
Participants: 15 810 apparently healthy Japanese adults not taking cholesterol-lowering drugs at baseline, with a mean body mass index of 22.5 kg/m(2) (SD 3.2).
Main outcome measures: Annual measurement of the serum total cholesterol (TC), low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, and calculation of the ratio of TC/HDL and LDL/HDL. Measurement of the ratio of long-term true change variation ('signal') to the short-term within-person variation ('noise') for each measure.
Results: At baseline, participants (53% male) with a mean age of 49 years (range 21-92) and a mean TC level of 5.3 mmol/l (SD 0.9 mmol/l) had annual check-ups over 4 years. Short-term within-person variations of TC, LDL, HDL, TC/HDL, and LDL/HDL were 0.12 (coefficient of variation (CV) 6.4%), 0.08 (CV 9.4%), 0.02 (CV 8.0%) mmol(2)/l(2), 0.08 (CV 7.9%) and 0.05 (CV 10.6%), respectively. The ratio of signal-to-noise at 3 years was largest for TC/HDL (1.6), followed by LDL/HDL (1.5), LDL (0.99), TC (0.8) and HDL (0.7), suggesting that cholesterol ratios are more sensitive re-screening measures.
Conclusion: The signal-to-noise ratios of standard single lipid measures (TC, LDL and HDL) are weak over 3 years and decisions based on these measures are potentially misleading. The ratios, TC/HDL and LDL/HDL, seem to be better measures for monitoring assessments. The lipid re-screening interval should be >3 years for those not taking cholesterol-lowering drugs.
Comment in
-
Which lipid fraction is the target and how often should this be monitored?Heart. 2010 Mar;96(6):413-4. doi: 10.1136/hrt.2009.177394. Heart. 2010. PMID: 20299412 No abstract available.
Similar articles
-
A long-term follow-up study of serum lipid levels and coronary heart disease in the elderly.Chin Med J (Engl). 2004 Feb;117(2):163-7. Chin Med J (Engl). 2004. PMID: 14975195
-
Association of total cholesterol versus other serum lipid parameters with the short-term prediction of cardiovascular outcomes: Tehran Lipid and Glucose Study.Eur J Cardiovasc Prev Rehabil. 2006 Aug;13(4):571-7. doi: 10.1097/01.hjr.0000216552.81882.ca. Eur J Cardiovasc Prev Rehabil. 2006. PMID: 16874147
-
Risk determination of dyslipidemia in populations characterized by low levels of high-density lipoprotein cholesterol.Am Heart J. 2003 Dec;146(6):1052-9. doi: 10.1016/S0002-8703(03)00516-7. Am Heart J. 2003. PMID: 14660998
-
A review of the treatment guidelines on the management of low levels of high-density lipoprotein cholesterol.Cardiology. 2004;102(2):61-6. doi: 10.1159/000077906. Epub 2004 Apr 19. Cardiology. 2004. PMID: 15103174 Review.
-
Epidemiologic aspects of lipid abnormalities.Am J Med. 1998 Jul 6;105(1A):48S-57S. doi: 10.1016/s0002-9343(98)00212-5. Am J Med. 1998. PMID: 9707268 Review.
Cited by
-
Which lipid measurement should we monitor? An analysis of the LIPID study.BMJ Open. 2014 Feb 21;4(2):e003512. doi: 10.1136/bmjopen-2013-003512. BMJ Open. 2014. PMID: 24561494 Free PMC article. Clinical Trial.
-
Omega-3 Index correlates with healthier food consumption in adolescents and with reduced cardiovascular disease risk factors in adolescent boys.Lipids. 2011 Jan;46(1):59-67. doi: 10.1007/s11745-010-3499-8. Epub 2010 Nov 20. Lipids. 2011. PMID: 21103948
-
The Importance of Understanding Variation.Indian J Clin Biochem. 2012 Jul;27(3):211-3. doi: 10.1007/s12291-012-0242-7. Epub 2012 Jul 17. Indian J Clin Biochem. 2012. PMID: 26405377 Free PMC article. No abstract available.
-
Frequency of Testing for Dyslipidemia: An Evidence-Based Analysis.Ont Health Technol Assess Ser. 2014 May 1;14(6):1-30. eCollection 2014. Ont Health Technol Assess Ser. 2014. PMID: 26316920 Free PMC article.
-
Implementation of the KDIGO guideline on lipid management requires a substantial increase in statin prescription rates.Kidney Int. 2015 Dec;88(6):1411-1418. doi: 10.1038/ki.2015.246. Epub 2015 Sep 2. Kidney Int. 2015. PMID: 26331409
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources